Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M.

Vaccine. 2003 Apr 2;21(15):1687-93.

PMID:
12639491
2.

MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

Puig Barberà J, González Vidal D.

Expert Rev Vaccines. 2007 Oct;6(5):659-65. Review.

PMID:
17931147
3.

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.

Podda A, Del Giudice G.

Expert Rev Vaccines. 2003 Apr;2(2):197-203. Review.

PMID:
12899571
4.

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM.

Hum Vaccin Immunother. 2015;11(3):553-63. doi: 10.1080/21645515.2015.1011562. Review.

5.
6.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
8.

MF59 adjuvant: the best insurance against influenza strain diversity.

O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G.

Expert Rev Vaccines. 2011 Apr;10(4):447-62. doi: 10.1586/erv.11.23. Review.

PMID:
21506643
9.

Pandemic H5N1 influenza vaccine development: an update.

El Sahly HM, Keitel WA.

Expert Rev Vaccines. 2008 Mar;7(2):241-7. doi: 10.1586/14760584.7.2.241. Review.

PMID:
18324892
10.

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

Leroux-Roels G.

Expert Opin Biol Ther. 2009 Aug;9(8):1057-71. doi: 10.1517/14712590903066695. Review.

PMID:
19555313
11.

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

El Sahly H.

Expert Rev Vaccines. 2010 Oct;9(10):1135-41. doi: 10.1586/erv.10.111. Review.

PMID:
20923265
13.

Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.

Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, Icardi G.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:29-40. Epub 2011 Jan 1. Review.

PMID:
21245655
14.

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.

Durando P, Icardi G, Ansaldi F.

Expert Opin Biol Ther. 2010 Apr;10(4):639-51. doi: 10.1517/14712591003724662. Review.

PMID:
20218923
15.

Recent advances in vaccine adjuvants for systemic and mucosal administration.

O'Hagan DT.

J Pharm Pharmacol. 1998 Jan;50(1):1-10. Review.

PMID:
9504429
16.

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Garçon N, Vaughn DW, Didierlaurent AM.

Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. Review.

PMID:
22380826
17.

Emulsion-based adjuvants for influenza vaccines.

Vogel FR, Caillet C, Kusters IC, Haensler J.

Expert Rev Vaccines. 2009 Apr;8(4):483-92. doi: 10.1586/erv.09.5. Review.

PMID:
19348563
18.

The mechanism of action of MF59 - an innately attractive adjuvant formulation.

O'Hagan DT, Ott GS, De Gregorio E, Seubert A.

Vaccine. 2012 Jun 19;30(29):4341-8. doi: 10.1016/j.vaccine.2011.09.061. Review. Erratum in: Vaccine. 2013 Apr 3;31(14):1877.

PMID:
22682289
19.

The history of MF59(®) adjuvant: a phoenix that arose from the ashes.

O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD.

Expert Rev Vaccines. 2013 Jan;12(1):13-30. doi: 10.1586/erv.12.140. Review.

PMID:
23256736
20.

[ADJUVANTED INFLUENZA VACCINES: DATA FROM DIRECT COMPARATIVE STUDIES].

Chernikova MI, Vasiliev YM.

Zh Mikrobiol Epidemiol Immunobiol. 2015 Sep-Oct;(5):88-102. Review. Russian.

PMID:
26829860

Supplemental Content

Support Center